VALN
HEALTHCAREValneva SE
$5.41+0.12 (+2.27%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VALN Today?
No stock-specific AI insight has been generated for VALN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.06$12.25
$5.41
Fundamentals
Market Cap$513M
P/E Ratio—
EPS$-1.59
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin-0.7%
Debt / Equity—
Trading
Volume42K
Avg Volume (10D)—
Shares Outstanding94.8M
VALN News
22 articles- Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026Yahoo Finance·May 5, 2026
- Valneva Announces the Successful Completion of an €84 million Reserved OfferingYahoo Finance·Apr 30, 2026
- Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13Yahoo Finance·Apr 20, 2026
- Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 DataYahoo Finance·Apr 7, 2026
- Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2026GlobeNewswire Inc.·Apr 3, 2026
- Declaration of shares and voting rights of Valneva SE – March 2026GlobeNewswire Inc.·Apr 3, 2026
- Will Pfizer’s Lyme disease gamble pay off or set the space back?Pharmavoice·Apr 1, 2026
- Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest DividendsYahoo Finance·Mar 30, 2026
- Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?Yahoo Finance·Mar 27, 2026
- Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 DataYahoo Finance·Mar 27, 2026
- Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DCYahoo Finance·Mar 26, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNGlobeNewswire Inc.·Mar 24, 2026
- VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine StudyYahoo Finance·Mar 24, 2026
- Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio StoryYahoo Finance·Mar 23, 2026
- Pfizer-Valneva Lyme disease vaccine falls short as low cases skew resultsClinicaltrialsarena·Mar 23, 2026
- Traders Digest Signs of Easing Middle East Tensions as US Equity Futures Rise Pre-BellYahoo Finance·Mar 23, 2026
- Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsBiopharmadive·Mar 23, 2026
- Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR TrialYahoo Finance·Mar 23, 2026
- Valneva Q4 Earnings Call HighlightsMarketbeat·Mar 18, 2026
- Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...Yahoo Finance·Mar 18, 2026
- Sector Update: Health Care Stocks Slip Late AfternoonYahoo Finance·Mar 18, 2026
All 22 articles loaded
Price Data
Open$5.41
Previous Close$5.29
Day High$5.50
Day Low$5.35
52 Week High$12.25
52 Week Low$5.06
52-Week Range
$5.06$12.25
$5.41
Fundamentals
Market Cap$513M
P/E Ratio—
EPS$-1.59
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin-0.7%
Debt / Equity—
Trading
Volume42K
Avg Volume (10D)—
Shares Outstanding94.8M
About Valneva SE
Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company is headquartered in Saint-Herblain, France.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—